Rahul K. Dhanda
Mr. Rahul Dhanda co-founded Sherlock Biosciences in early 2018. As the founding CEO and President, Mr. Dhanda scaled the company by building a diverse and accomplished team to reach commercialization of the first-ever CRISPR product, diagnostic or therapeutic, to be authorized by the FDA. A strong advocate of equity in society and STEM, Mr. Dhanda founded The 221b Foundation, a non-profit organization that provides access to CRISPR intellectual property for COVID-19 diagnostics, the profits of which are invested in STEM education initiatives promoting gender and racial diversity. Prior to Sherlock Biosciences, Mr. Dhanda helped build T2 Biosystems over ten years, resulting in a publicly-traded commercial leader in infectious disease diagnostics. Mr. Dhanda earned his MBA from MIT’s Sloan School of Management and his B.A. from Wesleyan University, and is the author of several publications and an inventor on numerous patents. He authored the first book to address the crossroads between industry and bioethics/public policy, entitled Guiding Icarus: Merging Bioethics with Corporate Interests.